mage-a1-specific t cell receptor-transduced autologous t-cells
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 19, 2021 (NCT04639245)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05430555 | Phase 1/Phase 2 (Phase 2) | Jul 29, 2022 | T-knife GmbH, University of California, San Francisco |
| NCT04639245 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2021 | SignalOne Bio, Inc., University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SignalOne Bio, Inc. | For profit | 1 | 0 | 1 | 2021 |
| T-knife GmbH | For profit | 1 | 1 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1